Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease
Anti amyloid beta therapeutics are compared by their diffusible aggregate binding characteristics. In-vitro and brain-derived aggregates are tested using single-molecule detection. Lecanemab shows therapeutic success by binding to aggregates formed in early disease. Lecanemab binds to these aggregates with high affinity and coats them better.
Authors
- Elizabeth A. English (ORCID: https://orcid.org/0000-0003-0348-9318)
- Giulia Albertini (ORCID: https://orcid.org/0000-0002-8215-2432)
- Bart De Strooper (ORCID: https://orcid.org/0000-0001-5455-5819)
- Maarten Dewilde (ORCID: https://orcid.org/0000-0002-3138-281X)
- Emre Fertan (ORCID: https://orcid.org/0000-0002-0060-5806)
- David A. Klenerman (ORCID: https://orcid.org/0000-0001-7116-6954)
- Jeff Y. L. Lam (ORCID: https://orcid.org/0000-0001-7408-2342)
- Oluwatomi E. Akingbade (ORCID: https://orcid.org/0000-0002-2510-2471)
- Dorothea Böken (ORCID: https://orcid.org/0009-0008-8443-4469)
- Yunzhao Wu
Institutions
- Hong Kong University of Science and Technology (HK)
- University of Cambridge (GB)
- UK Dementia Research Institute (GB)
- VIB-KU Leuven Center for Brain & Disease Research (BE)
- University College London (GB)
- University of Hong Kong (HK)
- KU Leuven (BE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/alz.70086
- Citations
- 21
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 24.45
Funders
- Alzheimer's Association
- European Commission
- UK Dementia Research Institute
- Medical Research Council